FDA Accepts New Drug Application for CeleCor’s Investigational Heart-Attack Drug Zalunfiban

NDA FilingZalunfibanPositive

AI Analysis

Summary

The FDA has accepted CeleCor Therapeutics' New Drug Application for zalunfiban, an investigational heart-attack drug, with a target action date of June 18, 2027.

Outcome Details

FDA accepted NDA for zalunfiban

Importance:7/10

Sentiment:

0.70

FDANDAcardiologyregulatory milestone

Related Companies

$CBDY

Read the original article

Published by Drugs.com New Drug Applications on September 30, 2026 2:09 AM

Read Original